LTS:0J9P (USA)
Business Description
Incyte Corp
NAICS : 541714
SIC : 8731
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Compare
Compare
Traded in other countries / regions
INCY.Austria
•
I1NC34.Brazil
•
ICY.Germany
•
INCY.Mexico
•
0J9P.UK
•
INCY.USA
Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 62.5 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 286.92 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 9.46 | |||||
| Beneish M-Score | -1.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.5 | |||||
| 3-Year EBITDA Growth Rate | 52.7 | |||||
| 3-Year EPS without NRI Growth Rate | 103.1 | |||||
| 3-Year FCF Growth Rate | 28.1 | |||||
| 3-Year Book Growth Rate | 23.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 32.11 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 14.86 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 35.95 | |||||
| 12-1 Month Momentum % | -3.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.91 | |||||
| Quick Ratio | 3.85 | |||||
| Cash Ratio | 2.94 | |||||
| Days Inventory | 64.27 | |||||
| Days Sales Outstanding | 61.92 | |||||
| Days Payable | 311.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.67 | |||||
| Operating Margin % | 22.03 | |||||
| Net Margin % | 28.46 | |||||
| ROE % | 26.54 | |||||
| ROA % | 20.18 | |||||
| ROIC % | 57.14 | |||||
| ROC (Joel Greenblatt) % | 86.34 | |||||
| ROCE % | 16.34 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.38 | |||||
| PE Ratio without NRI | 17.38 | |||||
| Shiller PE Ratio | 164.07 | |||||
| Price-to-Owner-Earnings | 43.94 | |||||
| PS Ratio | 4.95 | |||||
| PB Ratio | 4.01 | |||||
| Price-to-Tangible-Book | 4.32 | |||||
| Price-to-Free-Cash-Flow | 24.75 | |||||
| Price-to-Operating-Cash-Flow | 21.63 | |||||
| EV-to-EBIT | 21.76 | |||||
| EV-to-EBITDA | 19.8 | |||||
| EV-to-Revenue | 4.14 | |||||
| EV-to-FCF | 20.68 | |||||
| Price-to-Projected-FCF | 2.51 | |||||
| Price-to-Median-PS-Value | 0.45 | |||||
| Price-to-Graham-Number | 1.83 | |||||
| Price-to-Net-Current-Asset-Value | 6.85 | |||||
| Price-to-Net-Cash | 11 | |||||
| Earnings Yield (Greenblatt) % | 4.6 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,320.472 | ||
| EPS (TTM) ($) | 4.25 | ||
| Beta | 0.25 | ||
| Volatility % | 6.28 | ||
| 14-Day RSI | 35.95 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 71.4 | ||
| 12-1 Month Momentum % | -3.01 | ||
| 52-Week Range ($) | 71.4 - 79.63 | ||
| Shares Outstanding (Mil) | 222.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Incyte Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||